Literature DB >> 21071934

Chronic nitric oxide deficiency and progression of kidney disease after renal mass reduction in the C57Bl6 mouse.

Veronika Muller1, You-Lin Tain, Byron Croker, Chris Baylis.   

Abstract

BACKGROUND/AIMS: the C57Bl6 mouse is resistant to chronic kidney disease (CKD) induced by reduction of renal mass (RRM). Nitric oxide (NO) deficiency exacerbates CKD progression so this study investigated whether combination of RRM and NO deficiency would render the C57Bl6 mouse vulnerable to CKD.
METHODS: we used wild-type (WT) mice with RRM, chronic NO synthase (NOS) inhibition and a combination. Also, endothelial NOS (eNOS) knockout (KO) C57Bl6 mice were studied with and without RRM. Primary endpoints were albuminuria and structural damage.
RESULTS: both nonselective (+L-NAME) and neuronal NOS 'selective' (+7NI) NOS inhibition greatly exacerbated the albuminuria and structural damage seen with RRM in the WT mice; NOS inhibition alone had little effect. The eNOS KO mice showed marked structural damage and significant albuminuria in the shams and RRM produced minimal exacerbation of structural damage although the albuminuria was massively amplified.
CONCLUSION: these studies demonstrate that the C57Bl6 mouse is rendered vulnerable to RRM-induced CKD when concomitant NO deficiency is produced. This observation supports previous work in CKD-resistant rats and suggests that NO deficiency is required for progression of CKD. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071934      PMCID: PMC2992651          DOI: 10.1159/000322106

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

1.  The course of the remnant kidney model in mice.

Authors:  S Kren; T H Hostetter
Journal:  Kidney Int       Date:  1999-07       Impact factor: 10.612

2.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

3.  Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism.

Authors:  J J Boffa; P L Tharaux; S Placier; R Ardaillou; J C Dussaule; C Chatziantoniou
Journal:  Circulation       Date:  1999-11-02       Impact factor: 29.690

Review 4.  Nitric oxide synthases: structure, function and inhibition.

Authors:  W K Alderton; C E Cooper; R G Knowles
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

Review 5.  How does proteinuria cause progressive renal damage?

Authors:  Mauro Abbate; Carla Zoja; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 10.121

6.  Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-01       Impact factor: 3.619

7.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

8.  Role of nNOS in blood pressure regulation in eNOS null mutant mice.

Authors:  N Kurihara; M E Alfie; D H Sigmon; N E Rhaleb; E G Shesely; O A Carretero
Journal:  Hypertension       Date:  1998-11       Impact factor: 10.190

9.  A reproducible model for chronic renal failure in the mouse.

Authors:  R F Gagnon; W P Duguid
Journal:  Urol Res       Date:  1983

10.  Model of robust induction of glomerulosclerosis in mice: importance of genetic background.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

View more
  9 in total

Review 1.  Nitric oxide synthase derangements and hypertension in kidney disease.

Authors:  Chris Baylis
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

2.  Activation of nuclear factor erythroid 2-related factor 2 coordinates dimethylarginine dimethylaminohydrolase/PPAR-γ/endothelial nitric oxide synthase pathways that enhance nitric oxide generation in human glomerular endothelial cells.

Authors:  Zaiming Luo; Shakil Aslam; William J Welch; Christopher S Wilcox
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

3.  Effects of the antioxidant drug tempol on renal oxygenation in mice with reduced renal mass.

Authors:  En Yin Lai; Zaiming Luo; Maristela L Onozato; Earl H Rudolph; Glenn Solis; Pedro A Jose; Anton Wellstein; Shakil Aslam; Mark T Quinn; Kathy Griendling; Thu Le; Ping Li; Fredrik Palm; William J Welch; Christopher S Wilcox
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-04

4.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

5.  Assessment of vascular function in patients with chronic kidney disease.

Authors:  Kristen L Jablonski; Emily Decker; Loni Perrenoud; Jessica Kendrick; Michel Chonchol; Douglas R Seals; Diana Jalal
Journal:  J Vis Exp       Date:  2014-06-16       Impact factor: 1.355

6.  Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

Authors:  James A P Tomlinson; Ben Caplin; Olga Boruc; Claire Bruce-Cobbold; Pedro Cutillas; Dirk Dormann; Peter Faull; Rebecca C Grossman; Sanjay Khadayate; Valeria R Mas; Dorothea D Nitsch; Zhen Wang; Jill T Norman; Christopher S Wilcox; David C Wheeler; James Leiper
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

7.  Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.

Authors:  William Baldwin; Steven McRae; George Marek; David Wymer; Varinderpal Pannu; Chris Baylis; Richard J Johnson; Yuri Y Sautin
Journal:  Diabetes       Date:  2011-02-23       Impact factor: 9.461

8.  Developmental programming of hypertension and kidney disease.

Authors:  Euming Chong; Ihor V Yosypiv
Journal:  Int J Nephrol       Date:  2012-11-28

9.  Relationship between Endothelial Dysfunction and Prevalence of Chronic Kidney Disease: The Circulatory Risk in Communities Study (CIRCS).

Authors:  Yuting Li; Renzhe Cui; Keyang Liu; Ehab S Eshak; Meishan Cui; Jiayi Dong; Hironori Imano; Isao Muraki; Masahiko Kiyama; Akihiko Kitamura; Takeo Okada; Kazumasa Yamagishi; Mitsumasa Umesawa; Tetsuya Ohira; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2020-09-02       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.